Awards & Advancement

BRANY solution takes two 2015 app design awards

Thursday, October 8, 2015

ProtocolBuilder, a first-of-its-kind solution for writing clinical trial protocols, has received Gold Awards for “Best New Service Award or Application” and “Health Application” in the 2015 [app] design awards sponsored by design100. The awards celebrate creativity and innovation in design achievements by app creators and commissioners.

[Read More]

Arena President/CEO to step down

Wednesday, October 7, 2015

Arena Pharmaceuticals has announced that, at the request of the board of directors, company President and CEO Jack Lief has retired from the company, including the board. Dr. Harry Hixson, a director of Arena since 2004, has been appointed to serve as interim chief executive officer and interim principal financial officer. Arena will immediately initiate a search for a new chief executive.

[Read More]

EMD Serono appoints U.S. CMO

Wednesday, September 30, 2015

EMD Serono, the U.S. biopharmaceutical business of Germany-based Merck, has appointed Joseph Leveque, M.D., as U.S. chief medical officer. Leveque will be responsible for working with the regulatory, medical and development teams to enhance EMD Serono’s clinical presence in the U.S. and to drive the execution of crucial medical initiatives.

[Read More]

Exelixis adds top personnel

Monday, September 28, 2015

Exelixis has announced three high-level appointments as the company prepares for the potential commercialization of its lead compound, cabozantinib, for the treatment of advanced renal cell carcinoma (RCC) following positive results from the METEOR pivotal phase III trial. William Berg, M.D., has joined the company as senior vice president of medical affairs, Jonathan Berndt as vice president of sales, and Gregg Bernier as vice president of marketing.

[Read More]

Albireo appoints Cooper as CEO

Thursday, September 24, 2015

Ron Cooper has joined Albireo, a privately held company focused through its operating subsidiary on the development of bile acid modulators to treat orphan pediatric and adult liver diseases, NASH and gastrointestinal disorders, as president and chief executive officer.

[Read More]